What separates TB-500 from thymosin beta-4?

Seven amino acids separate TB-500 from a much larger evidence story.

Thymosin beta-4 is a naturally occurring 43-amino-acid peptide. The substance FDA evaluated as TB-500 is an acetylated seven-amino-acid fragment corresponding to positions 17 through 23 of that peptide: Ac-LKKTETQ.

They are related. They are not the same molecule.

That distinction changes almost every answer that follows. Human trials exist for full-length thymosin beta-4. In its 2026 review, FDA found no study or exposure record in which the TB-500 fragment was administered to a person by any route. A clinical result for the whole peptide cannot simply be reassigned to one fragment inside it.

TB-500 is a fragment, not a shorter spelling

The clearest identity record comes from two different directions.

In 2012, anti-doping researchers analyzed a product sold as TB-500. High- resolution mass spectrometry identified the N-terminally acetylated 17–23 fragment of human thymosin beta-4.

FDA reached the same structural description in its May 2026 compounding briefing. It treated TB-500 free base as the seven-residue sequence Ac-LKKTETQ, while full-length thymosin beta-4 contains 43 residues.

The difference is not cosmetic. A fragment can have different binding, metabolism, distribution, stability and biological activity from its parent peptide. Even adding an acetyl group changes the chemical entity being studied.

The name adds another problem. TB-500 is a common name, not a United States Adopted Name. FDA reported finding multiple salts, derivatives and even different active moieties sold under that label. A product page saying TB-500 therefore does not prove which substance is inside.

Even TB-500 does not identify one bulk substance

FDA evaluated TB-500 free base and TB-500 acetate separately. The acetate is a salt form of the free base, but the two are distinct bulk drug substances. Their physical properties, stability and finished-product behavior need not be identical.

The withdrawn nomination illustrated the problem. It named the free base, but the accompanying certificate of analysis described the acetate. Other identifiers in the package did not consistently match either substance.

That is not a paperwork footnote. It is the difference between a marketing label and a characterized active ingredient.

The direct TB-500 ledger is short

The foundational TB-500 paper was analytical, not therapeutic. It identified what was present in a product suspected of doping use. It did not treat an injury or test safety in people.

A 2024 study then tracked TB-500 metabolism in laboratory systems and rats. It also compared the parent compound and metabolites in a fibroblast scratch assay. The parent TB-500 did not significantly improve wound closure in that assay. One shorter metabolite, Ac-LKKTE, did.

That result is scientifically interesting because it makes the mechanism less simple: activity attributed to TB-500 may depend on what the parent becomes. But a scratch closing in cultured cells is not a tendon, muscle, ligament or clinical wound healing faster in a person.

FDA found no in-vivo pharmacology study assessing wound healing for the free base or acetate, no nonclinical toxicity package and no clinical study of either substance. Its direct evidence conclusion was therefore narrower and more severe than human research is early: human exposure data for TB-500 were not identified at all.

Full-length thymosin beta-4 has human studies

The search record looks larger because another molecule has made it into people.

In a 2015 randomized Phase II dry-eye trial, 72 participants received a topical full-length thymosin beta-4 formulation or placebo for 28 days. Neither of the two prespecified primary endpoints differed significantly at the specified visit. Several secondary measures and ad hoc analyses favored the active group.

That is a real human trial with a mixed result. It is also an eye-drop study of the full 43-amino-acid peptide.

A separate randomized dose-escalation study treated 73 people with venous ulcers using topical full-length thymosin beta-4. It reported an acceptable short-term safety profile and exploratory healing signals. Full-length synthetic thymosin beta-4 has also entered intravenous safety and pharmacokinetic studies in healthy volunteers. A separate 2021 Phase I program tested NL005, a 44-amino-acid recombinant human thymosin beta-4 product—not the seven-residue TB-500 fragment.

Those programs establish administered-human evidence for much larger thymosin beta-4 products. They do not prove that the seven-residue fragment accelerates recovery, and they do not establish a TB-500 safety profile.

Why the evidence cannot be borrowed

The online shortcut usually runs like this:

1. Thymosin beta-4 participates in actin-related cell biology.
2. TB-500 contains a sequence drawn from an actin-binding region.
3. Therefore, thymosin beta-4 studies validate TB-500 recovery claims.

Step three is the unsupported jump.

Moving evidence from one molecule to another requires more than a shared sequence. The actual substance, formulation, route, exposure, metabolites and clinical condition all matter. The full peptide’s topical eye and ulcer trials are especially poor substitutes for a fragment promoted for injected musculoskeletal recovery.

This is also why phrases such as synthetic thymosin beta-4 create trouble. They can correctly describe a manufactured full-length copy, or incorrectly collapse TB-500 into the whole 43-residue peptide. The sequence and product identity must do the work that the nickname cannot.

The July FDA vote changed advice, not evidence

FDA staff proposed against adding TB-500 free base and TB-500 acetate to the section 503A Bulks List. The review cited inconsistent identity records, gaps in characterization, no direct human effectiveness evidence and unknown human safety.

On 23 July 2026, the Pharmacy Compounding Advisory Committee voted 8–6–1 to recommend listing each form for the question it was asked. That recommendation differed from the staff proposal.

It was not an approval, a clinical-trial result or a final agency decision. As of 3 August, FDA’s public safety-risk page still listed the thymosin beta-4 fragment known as TB-500 in its table of withdrawn nominations previously in Category 2, with the human-exposure and immunogenicity concerns intact.

The hearing changed the advisory record. It did not merge the molecules or add a participant to the TB-500 evidence base.

Athletes face a separate rule

The 2026 World Anti-Doping Agency list names thymosin beta-4 and its derivatives, with TB-500 as the example, under growth factors and growth-factor modulators.

That makes the substance a serious anti-doping issue for athletes covered by the code. It does not mean WADA has declared TB-500 chemically identical to full-length thymosin beta-4, and it does not answer whether either substance is effective or generally lawful in every setting.

FDA approval, compounding policy, clinical evidence and anti-doping rules are four different questions.

Primary sources

• FDA 2026 TB-500 briefing
• FDA current compounding safety-risk page
• Esposito et al., analytical identification of the TB-500 fragment
• Rahaman et al., TB-500 metabolism and wound-closure assays
• Full-length thymosin beta-4 dry-eye trial
• Full-length thymosin beta-4 venous-ulcer trial
• Full-length intravenous thymosin beta-4 study
• 44-amino-acid recombinant human thymosin beta-4 Phase I study
• WADA 2026 Prohibited List

Independent editorial summary. The authors, agencies and organizations are not affiliated with LifeScore.